{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:09:57Z","timestamp":1793956197826,"version":"4.8.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82403859"],"award-info":[{"award-number":["82403859"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ6544"],"award-info":[{"award-number":["2024JJ6544"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Changsha","award":["kq2402235"],"award-info":[{"award-number":["kq2402235"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03153-x","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:20:02Z","timestamp":1764732002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting DNA damage response to enhance cancer immunotherapy efficacy: molecular mechanisms and clinical advances"],"prefix":"10.1007","volume":"43","author":[{"given":"Ziyi","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0648-0565","authenticated-orcid":false,"given":"Zhaoyang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"7267","key":"3153_CR1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071\u20138.","journal-title":"Nature"},{"issue":"7","key":"3153_CR2","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1158\/2159-8290.CD-22-1220","volume":"13","author":"V Klapp","year":"2023","unstructured":"Klapp V, et al. The DNA damage response and inflammation in cancer. Cancer Discov. 2023;13(7):1521\u201345.","journal-title":"Cancer Discov"},{"issue":"5","key":"3153_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","volume":"10","author":"S Morganti","year":"2024","unstructured":"Morganti S, et al. PARP inhibitors for breast cancer treatment: a review. JAMA Oncol. 2024;10(5):658\u201370.","journal-title":"JAMA Oncol"},{"issue":"1","key":"3153_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13045-022-01360-x","volume":"15","author":"S Li","year":"2022","unstructured":"Li S, et al. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment. J Hematol Oncol. 2022;15(1):147.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3153_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly FJ, et al. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23(2):78\u201394.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3153_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pili\u00e9","year":"2019","unstructured":"Pili\u00e9 PG, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81\u2013104.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3153_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","volume":"24","author":"M Zhang","year":"2025","unstructured":"Zhang M, et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer. 2025;24(1):136.","journal-title":"Mol Cancer"},{"issue":"1","key":"3153_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, et al. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023;8(1):320.","journal-title":"Signal Transduct Target Ther"},{"issue":"22","key":"3153_CR9","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA. 2024;332(22):1924\u201335.","journal-title":"JAMA"},{"issue":"7","key":"3153_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","volume":"25","author":"N Zaidi","year":"2025","unstructured":"Zaidi N, Jaffee EM, Yarchoan M. Recent advances in therapeutic cancer vaccines. Nat Rev Cancer. 2025;25(7):517\u201333.","journal-title":"Nat Rev Cancer"},{"key":"3153_CR11","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14:1212476.","journal-title":"Front Immunol"},{"issue":"7970","key":"3153_CR12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-023-06069-6","volume":"619","author":"AVR Kornepati","year":"2023","unstructured":"Kornepati AVR, et al. The complementarity of DDR, nucleic acids and anti-tumour immunity. Nature. 2023;619(7970):475\u201386.","journal-title":"Nature"},{"issue":"1","key":"3153_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","volume":"12","author":"P Zhao","year":"2019","unstructured":"Zhao P, et al. Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12(1):54.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"3153_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41419-024-06911-3","volume":"15","author":"C Li","year":"2024","unstructured":"Li C, et al. ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC class I. Cell Death Dis. 2024;15(7):519.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3153_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","volume":"24","author":"Y Drew","year":"2025","unstructured":"Drew Y, Zenke FT, Curtin NJ. DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nat Rev Drug Discov. 2025;24(1):19\u201339.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"3153_CR16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.tig.2024.08.009","volume":"40","author":"D Huang","year":"2024","unstructured":"Huang D, et al. The complex universe of inactive PARP1. Trends Genet. 2024;40(12):1074\u201385.","journal-title":"Trends Genet"},{"issue":"1","key":"3153_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/med.22069","volume":"45","author":"YR Bai","year":"2025","unstructured":"Bai YR, et al. The recent advance and prospect of poly(ADP-ribose) polymerase inhibitors for the treatment of cancer. Med Res Rev. 2025;45(1):214\u201373.","journal-title":"Med Res Rev"},{"issue":"7","key":"3153_CR18","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1158\/2159-8290.CD-20-1503","volume":"11","author":"J Setton","year":"2021","unstructured":"Setton J, et al. Synthetic lethality in cancer therapeutics: the next generation. Cancer Discov. 2021;11(7):1626\u201335.","journal-title":"Cancer Discov"},{"key":"3153_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102650","volume":"121","author":"L Incorvaia","year":"2023","unstructured":"Incorvaia L, et al. Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: still looking through a dirty glass window? Cancer Treat Rev. 2023;121:102650.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"3153_CR20","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s11912-022-01337-6","volume":"24","author":"CR Washington","year":"2022","unstructured":"Washington CR, Moore KN. Resistance to poly (ADP-ribose) polymerase inhibitors (PARPi): mechanisms and potential to reverse. Curr Oncol Rep. 2022;24(12):1685\u201393.","journal-title":"Curr Oncol Rep"},{"issue":"22","key":"3153_CR21","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"15","key":"3153_CR22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.2217\/fon-2018-0751","volume":"15","author":"KE McCann","year":"2019","unstructured":"McCann KE. Advances in the use of PARP inhibitors for BRCA1\/2-associated breast cancer: talazoparib. Future Oncol. 2019;15(15):1707\u201315.","journal-title":"Future Oncol"},{"issue":"7","key":"3153_CR23","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1016\/S1470-2045(22)00325-4","volume":"23","author":"S Ganguly","year":"2022","unstructured":"Ganguly S, Gogia A. Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations. Lancet Oncol. 2022;23(7):e314.","journal-title":"Lancet Oncol"},{"key":"3153_CR24","doi-asserted-by":"publisher","first-page":"p979873","DOI":"10.3389\/fphar.2022.979873","volume":"13","author":"J Zheng","year":"2022","unstructured":"Zheng J, Li Z, Min W. Current status and future promise of next-generation Poly (ADP-Ribose) Polymerase 1-selective inhibitor AZD5305. Front Pharmacol. 2022;13:p979873.","journal-title":"Front Pharmacol"},{"issue":"7","key":"3153_CR25","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-23-2094","volume":"30","author":"AD Staniszewska","year":"2024","unstructured":"Staniszewska AD, et al. Preclinical characterization of AZD9574, a Blood-Brain barrier penetrant inhibitor of PARP1. Clin Cancer Res. 2024;30(7):1338\u201351.","journal-title":"Clin Cancer Res"},{"key":"3153_CR26","doi-asserted-by":"publisher","first-page":"102808","DOI":"10.1016\/j.ctrv.2024.102808","volume":"129","author":"JH Lee","year":"2024","unstructured":"Lee JH. Targeting the ATM pathway in cancer: Opportunities, challenges and personalized therapeutic strategies. Cancer Treat Rev. 2024;129:102808.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"3153_CR27","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/1535-7163.MCT-21-0934","volume":"21","author":"A Zimmermann","year":"2022","unstructured":"Zimmermann A, et al. A new class of selective ATM inhibitors as combination partners of DNA Double-Strand break inducing cancer therapies. Mol Cancer Ther. 2022;21(6):859\u201370.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"3153_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/1535-7163.MCT-23-0890","volume":"23","author":"TM Gilmer","year":"2024","unstructured":"Gilmer TM, et al. A novel dual ATM\/DNA-PK Inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors. Mol Cancer Ther. 2024;23(6):751\u201365.","journal-title":"Mol Cancer Ther"},{"issue":"734","key":"3153_CR29","doi-asserted-by":"publisher","first-page":"eadj5962","DOI":"10.1126\/scitranslmed.adj5962","volume":"16","author":"J Chen","year":"2024","unstructured":"Chen J, et al. Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Sci Transl Med. 2024;16(734):eadj5962.","journal-title":"Sci Transl Med"},{"key":"3153_CR30","doi-asserted-by":"crossref","unstructured":"Xue Z, et al. The novel brain penetrant ATM inhibitor WSD0628 provides robust radiosensitization of brain tumor patient derived xenografts. Neuro Oncol; 2025.","DOI":"10.1093\/neuonc\/noaf102"},{"key":"3153_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-med-042320-025136","volume":"73","author":"NYL Ngoi","year":"2022","unstructured":"Ngoi NYL, Peng G, Yap TA. A tale of two checkpoints: ATR inhibition and PD-(L)1 blockade. Annu Rev Med. 2022;73:231\u201350.","journal-title":"Annu Rev Med"},{"key":"3153_CR32","doi-asserted-by":"publisher","first-page":"e2300635","DOI":"10.1200\/PO.23.00635","volume":"8","author":"PA Konstantinopoulos","year":"2024","unstructured":"Konstantinopoulos PA, et al. Randomized phase II study of gemcitabine with or without ATR inhibitor Berzosertib in Platinum-Resistant ovarian cancer: final overall survival and biomarker analyses. JCO Precis Oncol. 2024;8:e2300635.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"3153_CR33","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim H, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11(1):3726.","journal-title":"Nat Commun"},{"issue":"4","key":"3153_CR34","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1535-7163.MCT-23-0094","volume":"23","author":"FF Pusch","year":"2024","unstructured":"Pusch FF, et al. Elimusertib has antitumor activity in preclinical Patient-Derived pediatric solid tumor models. Mol Cancer Ther. 2024;23(4):507\u201319.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"3153_CR35","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, et al. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023;29(6):1400\u201311.","journal-title":"Nat Med"},{"issue":"11","key":"3153_CR36","volume":"5","author":"G Federica","year":"2024","unstructured":"Federica G, Michela C, Giovanna D. Targeting the DNA damage response in cancer. MedComm (2020). 2024;5(11):e788.","journal-title":"MedComm (2020)"},{"issue":"7","key":"3153_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.613","volume":"5","author":"J Wu","year":"2024","unstructured":"Wu J, et al. The multifaceted functions of DNA-PKcs: implications for the therapy of human diseases. MedComm. 2024;5(7):e613.","journal-title":"MedComm"},{"issue":"4","key":"3153_CR38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.14348\/molcells.2023.2164","volume":"46","author":"YR Lee","year":"2023","unstructured":"Lee YR, et al. DNA-Dependent protein kinase catalytic subunit (DNA-PKcs): beyond the DNA Double-Strand break repair. Mol Cells. 2023;46(4):200\u20135.","journal-title":"Mol Cells"},{"key":"3153_CR39","doi-asserted-by":"publisher","first-page":"106162","DOI":"10.1016\/j.phrs.2022.106162","volume":"178","author":"N Gupta","year":"2022","unstructured":"Gupta N, et al. Cell cycle checkpoints and beyond: exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer. Pharmacol Res. 2022;178:106162.","journal-title":"Pharmacol Res"},{"key":"3153_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cells14100748","author":"A Fernandez","year":"2025","unstructured":"Fernandez A, et al. Cancer vulnerabilities through targeting the ATR\/Chk1 and ATM\/Chk2 axes in the context of DNA damage. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14100748.","journal-title":"Cells"},{"issue":"12","key":"3153_CR41","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/13543784.2019.1694661","volume":"28","author":"P Dent","year":"2019","unstructured":"Dent P. Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer. Expert Opin Investig Drugs. 2019;28(12):1095\u2013100.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"3153_CR42","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/s41467-024-47215-6","volume":"15","author":"E Giudice","year":"2024","unstructured":"Giudice E, et al. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. Nat Commun. 2024;15(1):2805.","journal-title":"Nat Commun"},{"issue":"7","key":"3153_CR43","doi-asserted-by":"publisher","first-page":"109978","DOI":"10.1016\/j.isci.2024.109978","volume":"27","author":"H Xu","year":"2024","unstructured":"Xu H, et al. CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience. 2024;27(7):109978.","journal-title":"iScience"},{"issue":"1","key":"3153_CR44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12885-021-09138-z","volume":"22","author":"SJ Park","year":"2022","unstructured":"Park SJ, et al. A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer. BMC Cancer. 2022;22(1):28.","journal-title":"BMC Cancer"},{"key":"3153_CR45","doi-asserted-by":"publisher","first-page":"104710","DOI":"10.1016\/j.critrevonc.2025.104710","volume":"211","author":"K Thangaretnam","year":"2025","unstructured":"Thangaretnam K, et al. WEE1 Inhibition in cancer therapy: Mechanisms, synergies, preclinical insights, and clinical trials. Crit Rev Oncol Hematol. 2025;211:104710.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3153_CR46","doi-asserted-by":"publisher","first-page":"104233","DOI":"10.1016\/j.critrevonc.2023.104233","volume":"193","author":"C Zhang","year":"2024","unstructured":"Zhang C, et al. Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors. Crit Rev Oncol Hematol. 2024;193:104233.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3153_CR47","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-1194","author":"J Ma","year":"2025","unstructured":"Ma J, et al. Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumors. Mol Cancer Ther. 2025. https:\/\/doi.org\/10.1158\/1535-7163.MCT-24-1194.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"3153_CR48","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/ijgc-2022-003698","volume":"33","author":"P Soberanis Pina","year":"2023","unstructured":"Soberanis Pina P, Lheureux S. Overcoming PARP inhibitor resistance in ovarian cancer. Int J Gynecol Cancer. 2023;33(3):364\u201376.","journal-title":"Int J Gynecol Cancer"},{"key":"3153_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-med-081313-121208","volume":"66","author":"M Goldstein","year":"2015","unstructured":"Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med. 2015;66:129\u201343.","journal-title":"Annu Rev Med"},{"key":"3153_CR50","doi-asserted-by":"publisher","first-page":"100907","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang K, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 Blockade. Drug Resist Updat. 2023;66:100907.","journal-title":"Drug Resist Updat"},{"issue":"7","key":"3153_CR51","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","volume":"10","author":"T Yasuda","year":"2024","unstructured":"Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024;10(7):627\u201342.","journal-title":"Trends Cancer"},{"issue":"6","key":"3153_CR52","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","volume":"35","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Tumor mutational burden for the prediction of PD-(L)1 Blockade efficacy in cancer: challenges and opportunities. Ann Oncol. 2024;35(6):508\u201322.","journal-title":"Ann Oncol"},{"issue":"5","key":"3153_CR53","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.molcel.2022.12.031","volume":"83","author":"K Concannon","year":"2023","unstructured":"Concannon K, et al. Combining targeted DNA repair Inhibition and immune-oncology approaches for enhanced tumor control. Mol Cell. 2023;83(5):660\u201380.","journal-title":"Mol Cell"},{"key":"3153_CR54","doi-asserted-by":"publisher","first-page":"1487378","DOI":"10.3389\/fimmu.2024.1487378","volume":"15","author":"S Tokita","year":"2024","unstructured":"Tokita S, Kanaseki T, Torigoe T. Neoantigen prioritization based on antigen processing and presentation. Front Immunol. 2024;15:1487378.","journal-title":"Front Immunol"},{"issue":"6230","key":"3153_CR55","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 Blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138.","journal-title":"Science"},{"issue":"1","key":"3153_CR56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13073-019-0684-0","volume":"11","author":"ER Mardis","year":"2019","unstructured":"Mardis ER. Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response. Genome Med. 2019;11(1):71.","journal-title":"Genome Med"},{"issue":"5","key":"3153_CR57","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10120-024-01523-4","volume":"27","author":"A Ooki","year":"2024","unstructured":"Ooki A, et al. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and\/or deficient mismatch repair. Gastric Cancer. 2024;27(5):907\u201331.","journal-title":"Gastric Cancer"},{"issue":"8","key":"3153_CR58","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/1078-0432.CCR-21-1935","volume":"30","author":"HC Wilbur","year":"2024","unstructured":"Wilbur HC, Le DT, Agarwal P. Immunotherapy of MSI cancer: facts and hopes. Clin Cancer Res. 2024;30(8):1438\u201347.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3153_CR59","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13046-022-02422-1","volume":"41","author":"X Ma","year":"2022","unstructured":"Ma X, et al. POLE\/POLD1 mutation and tumor immunotherapy. J Exp Clin Cancer Res. 2022;41(1):216.","journal-title":"J Exp Clin Cancer Res"},{"key":"3153_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal4922","author":"E Nolan","year":"2017","unstructured":"Nolan E, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aal4922.","journal-title":"Sci Transl Med"},{"issue":"22","key":"3153_CR61","doi-asserted-by":"publisher","first-page":"6486","DOI":"10.1158\/0008-5472.CAN-18-1814","volume":"78","author":"Z Wang","year":"2018","unstructured":"Wang Z, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint Blockade. Cancer Res. 2018;78(22):6486\u201396.","journal-title":"Cancer Res"},{"key":"3153_CR62","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180278","author":"AJ Nielsen","year":"2024","unstructured":"Nielsen AJ, et al. DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI180278.","journal-title":"J Clin Invest"},{"issue":"6","key":"3153_CR63","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, et al. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23(6):445\u201360.","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"3153_CR64","doi-asserted-by":"publisher","first-page":"e2201734","DOI":"10.1002\/advs.202201734","volume":"9","author":"Z Li","year":"2022","unstructured":"Li Z, et al. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv Sci (Weinh). 2022;9(22):e2201734.","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"3153_CR65","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1158\/0008-5472.CAN-18-2807","volume":"79","author":"E Comb\u00e8s","year":"2019","unstructured":"Comb\u00e8s E, et al. Inhibition of Ataxia-Telangiectasia mutated and RAD3-Related (ATR) overcomes oxaliplatin resistance and promotes antitumor immunity in colorectal cancer. Cancer Res. 2019;79(11):2933\u201346.","journal-title":"Cancer Res"},{"key":"3153_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009032","author":"Y Xia","year":"2024","unstructured":"Xia Y, et al. PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD\/E axis in ovarian cancer. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-009032.","journal-title":"J Immunother Cancer"},{"key":"3153_CR67","doi-asserted-by":"publisher","first-page":"101600","DOI":"10.1016\/j.tranon.2022.101600","volume":"27","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. Identification and validation of novel Immunogenic cell Death- and DNA damage Response-Related molecular patterns correlated with immune status and prognosis in hepatocellular carcinoma. Transl Oncol. 2023;27:101600.","journal-title":"Transl Oncol"},{"issue":"1","key":"3153_CR68","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23(1):108.","journal-title":"Mol Cancer"},{"key":"3153_CR69","doi-asserted-by":"publisher","first-page":"216642","DOI":"10.1016\/j.canlet.2024.216642","volume":"586","author":"C Liu","year":"2024","unstructured":"Liu C, et al. Inhibition of ATM promotes PD-L1 expression by activating JNK\/c-Jun\/TNF-\u03b1 signaling axis in triple-negative breast cancer. Cancer Lett. 2024;586:216642.","journal-title":"Cancer Lett"},{"issue":"1","key":"3153_CR70","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","volume":"8","author":"H Sato","year":"2017","unstructured":"Sato H, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8(1):1751.","journal-title":"Nat Commun"},{"issue":"11","key":"3153_CR71","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1111\/cas.15961","volume":"114","author":"T Wang","year":"2023","unstructured":"Wang T, et al. Combination of PARP inhibitor and CDK4\/6 inhibitor modulates cGAS\/STING-dependent therapy-induced senescence and provides one-two punch opportunity with anti-PD-L1 therapy in colorectal cancer. Cancer Sci. 2023;114(11):4184\u2013201.","journal-title":"Cancer Sci"},{"key":"3153_CR72","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165934","author":"G Oh","year":"2023","unstructured":"Oh G, et al. POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS\/STING signaling. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI165934.","journal-title":"J Clin Invest"},{"key":"3153_CR73","doi-asserted-by":"publisher","first-page":"12632","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.","journal-title":"Nat Commun"},{"issue":"11","key":"3153_CR74","first-page":"2442","volume":"9","author":"B Zhou","year":"2019","unstructured":"Zhou B, et al. Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma. Am J Cancer Res. 2019;9(11):2442\u201355.","journal-title":"Am J Cancer Res"},{"issue":"41","key":"3153_CR75","doi-asserted-by":"publisher","first-page":"43472","DOI":"10.18632\/oncotarget.6179","volume":"6","author":"M Scarpa","year":"2015","unstructured":"Scarpa M, et al. Mismatch repair gene defects in sporadic colorectal cancer enhance immune surveillance. Oncotarget. 2015;6(41):43472\u201382.","journal-title":"Oncotarget"},{"issue":"3","key":"3153_CR76","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/cjp2.260","volume":"8","author":"X Chen","year":"2022","unstructured":"Chen X, et al. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma. J Pathol Clin Res. 2022;8(3):268\u201378.","journal-title":"J Pathol Clin Res"},{"issue":"3","key":"3153_CR77","doi-asserted-by":"publisher","first-page":"981","DOI":"10.7150\/ijbs.79852","volume":"19","author":"S Zheng","year":"2023","unstructured":"Zheng S, et al. Galectin-9 Blockade synergizes with ATM Inhibition to induce potent anti-tumor immunity. Int J Biol Sci. 2023;19(3):981\u201393.","journal-title":"Int J Biol Sci"},{"issue":"12","key":"3153_CR78","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022;3(12):1452\u201363.","journal-title":"Nat Cancer"},{"issue":"1","key":"3153_CR79","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","volume":"80","author":"T Reisl\u00e4nder","year":"2020","unstructured":"Reisl\u00e4nder T, Groelly FJ, Tarsounas M. DNA damage and cancer immunotherapy: a STING in the tale. Mol Cell. 2020;80(1):21\u20138.","journal-title":"Mol Cell"},{"issue":"4","key":"3153_CR80","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.immuni.2024.02.019","volume":"57","author":"S Dvorkin","year":"2024","unstructured":"Dvorkin S, et al. New frontiers in the cGAS-STING intracellular DNA-sensing pathway. Immunity. 2024;57(4):718\u201330.","journal-title":"Immunity"},{"issue":"1","key":"3153_CR81","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ccell.2020.11.006","volume":"39","author":"C Lu","year":"2021","unstructured":"Lu C, et al. DNA sensing in mismatch Repair-Deficient tumor cells is essential for Anti-tumor immunity. Cancer Cell. 2021;39(1):96\u2013108. .e6.","journal-title":"Cancer Cell"},{"key":"3153_CR82","doi-asserted-by":"publisher","first-page":"e29259","DOI":"10.4161\/onci.29259","volume":"3","author":"N Le Bert","year":"2014","unstructured":"Le Bert N, et al. STING-dependent cytosolic DNA sensor pathways regulate NKG2D ligand expression. Oncoimmunology. 2014;3:e29259.","journal-title":"Oncoimmunology"},{"key":"3153_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008460","author":"R Baugh","year":"2024","unstructured":"Baugh R, et al. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-008460.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"3153_CR84","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","volume":"21","author":"RM Chabanon","year":"2021","unstructured":"Chabanon RM, et al. Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nat Rev Cancer. 2021;21(11):701\u201317.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"3153_CR85","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek SM, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. Lancet Oncol. 2020;21(9):1155\u201364.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3153_CR86","doi-asserted-by":"publisher","first-page":"189282","DOI":"10.1016\/j.bbcan.2025.189282","volume":"1880","author":"CJF Concei\u00e7\u00e3o","year":"2025","unstructured":"Concei\u00e7\u00e3o CJF, et al. PARP1: A comprehensive review of its mechanisms, therapeutic implications and emerging cancer treatments. Biochim Biophys Acta Rev Cancer. 2025;1880(2):189282.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"11","key":"3153_CR87","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","volume":"3","author":"T Higuchi","year":"2015","unstructured":"Higuchi T, et al. CTLA-4 Blockade synergizes therapeutically with PARP Inhibition in BRCA1-Deficient ovarian cancer. Cancer Immunol Res. 2015;3(11):1257\u201368.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"3153_CR88","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","volume":"23","author":"KA Reiss","year":"2022","unstructured":"Reiss KA, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial. Lancet Oncol. 2022;23(8):1009\u201320.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3153_CR89","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","volume":"33","author":"R Kim","year":"2022","unstructured":"Kim R, et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy. Ann Oncol. 2022;33(2):193\u2013203.","journal-title":"Ann Oncol"},{"key":"3153_CR90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005041","author":"M Kwon","year":"2022","unstructured":"Kwon M, et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005041.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"3153_CR91","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s00262-021-02910-x","volume":"70","author":"KT Do","year":"2021","unstructured":"Do KT, et al. Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors. Cancer Immunol Immunother. 2021;70(10):2991\u20133000.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3153_CR92","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11523-024-01110-8","volume":"20","author":"MR Patel","year":"2025","unstructured":"Patel MR, et al. Open-Label, Multicenter, phase I study to assess safety and tolerability of Adavosertib plus durvalumab in patients with advanced solid tumors. Target Oncol. 2025;20(1):127\u201338.","journal-title":"Target Oncol"},{"issue":"1","key":"3153_CR93","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13046-022-02469-0","volume":"41","author":"C Shi","year":"2022","unstructured":"Shi C, et al. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. J Exp Clin Cancer Res. 2022;41(1):268.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3153_CR94","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","volume":"7","author":"JS Brown","year":"2017","unstructured":"Brown JS, et al. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov. 2017;7(1):20\u201337.","journal-title":"Cancer Discov"},{"key":"3153_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061502","author":"F Peyraud","year":"2020","unstructured":"Peyraud F, Italiano A. Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12061502.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"3153_CR96","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","volume":"129","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, et al. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023;129(6):904\u201316.","journal-title":"Br J Cancer"},{"issue":"1","key":"3153_CR97","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13045-021-01168-1","volume":"14","author":"F Ji","year":"2021","unstructured":"Ji F, et al. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway. J Hematol Oncol. 2021;14(1):152.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3153_CR98","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ymthe.2020.09.034","volume":"29","author":"R Sun","year":"2021","unstructured":"Sun R, et al. Olaparib suppresses MDSC recruitment via SDF1\u03b1\/CXCR4 axis to improve the Anti-tumor efficacy of CAR-T cells on breast cancer in mice. Mol Ther. 2021;29(1):60\u201374.","journal-title":"Mol Ther"},{"issue":"1","key":"3153_CR99","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41467-024-55751-4","volume":"16","author":"T Zhu","year":"2025","unstructured":"Zhu T, et al. Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung. Nat Commun. 2025;16(1):262.","journal-title":"Nat Commun"},{"key":"3153_CR100","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200844","author":"N Xu","year":"2021","unstructured":"Xu N, et al. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J Exp Med. 2021. https:\/\/doi.org\/10.1084\/jem.20200844.","journal-title":"J Exp Med"},{"issue":"1","key":"3153_CR101","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1038\/s41467-022-30568-1","volume":"13","author":"Q Wang","year":"2022","unstructured":"Wang Q, et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP Inhibition in BRCA1-deficient models of breast cancer. Nat Commun. 2022;13(1):3022.","journal-title":"Nat Commun"},{"issue":"10","key":"3153_CR102","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/0008-5472.CAN-25-0831","volume":"85","author":"Z Gohari","year":"2025","unstructured":"Gohari Z, Stojanovic L, Rassool FV. Combining STING agonists with PARP inhibitors mounts an NK-dependent defense against therapy-resistant breast cancer. Cancer Res. 2025;85(10):1747\u20139.","journal-title":"Cancer Res"},{"issue":"797","key":"3153_CR103","doi-asserted-by":"publisher","first-page":"eadr5861","DOI":"10.1126\/scitranslmed.adr5861","volume":"17","author":"J Liu","year":"2025","unstructured":"Liu J, et al. Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacy. Sci Transl Med. 2025;17(797):eadr5861.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3153_CR104","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou S, et al. The landscape of bispecific T cell engager in cancer treatment. Biomark Res. 2021;9(1):38.","journal-title":"Biomark Res"},{"key":"3153_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00553-7","author":"O Pail","year":"2025","unstructured":"Pail O, et al. Cancer vaccines and the future of immunotherapy. Lancet. 2025. https:\/\/doi.org\/10.1016\/S0140-6736(25)00553-7.","journal-title":"Lancet"},{"issue":"7916","key":"3153_CR106","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41586-022-04772-4","volume":"606","author":"S Badrinath","year":"2022","unstructured":"Badrinath S, et al. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature. 2022;606(7916):992\u20138.","journal-title":"Nature"},{"issue":"3","key":"3153_CR107","doi-asserted-by":"publisher","first-page":"101981","DOI":"10.1016\/j.xcrm.2025.101981","volume":"6","author":"R Wang","year":"2025","unstructured":"Wang R, et al. An epitope-directed mRNA vaccine inhibits tumor metastasis through the Blockade of MICA\/B \u03b11\/2 shedding. Cell Rep Med. 2025;6(3):101981.","journal-title":"Cell Rep Med"},{"issue":"6","key":"3153_CR108","doi-asserted-by":"publisher","first-page":"115733","DOI":"10.1016\/j.celrep.2025.115733","volume":"44","author":"II Ng","year":"2025","unstructured":"Ng II, et al. Targeting WEE1 in tumor-associated dendritic cells potentiates antitumor immunity via the cGAS\/STING pathway. Cell Rep. 2025;44(6):115733.","journal-title":"Cell Rep"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03153-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03153-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03153-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:03:07Z","timestamp":1769490187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03153-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":108,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3153"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03153-x","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval"}}],"article-number":"33"}}